Angiogenesis modulated by CD93 and its natural ligands IGFBP7 and MMRN2: a new target to facilitate solid tumor...

Area of Science:

• Biomedical Science
• Cancer Research
• Molecular Biology

Background:

• Tumor vasculature differs functionally and morphologically from normal vasculature, leading to tumor microenvironment (TME) hypoxia.
• Previous anti-angiogenesis therapies offered limited benefits and caused side effects, necessitating novel therapeutic strategies.
• The CD93 receptor, expressed on endothelial cells, and its ligands, IGFBP7 and MMRN2, are emerging targets for anti-angiogenic treatment.

Purpose of the Study:

• To review the role of CD93, IGFBP7, and MMRN2 in angiogenesis.
• To elucidate the interactions between IGFBP7-CD93 and MMRN2-CD93 signaling pathways.
• To examine the clinical relevance of CD93, IGFBP7, and MMRN2 expression in cancer.

Main Methods:

• Literature review of recent studies on CD93, IGFBP7, and MMRN2 in angiogenesis.
• Analysis of signaling cascades influenced by CD93, IGFBP7, and MMRN2.
• Review of retrospective studies correlating CD93, IGFBP7, and MMRN2 expression with clinical factors.

Main Results:

• CD93, IGFBP7, and MMRN2 play significant roles in the angiogenesis process.
• Specific interactions between IGFBP7-CD93 and MMRN2-CD93 influence signaling pathways.
• Expression patterns of CD93, IGFBP7, and MMRN2 correlate with clinical parameters in cancer patients.

Conclusions:

• CD93 is a potential therapeutic target for normalizing tumor vasculature.
• Targeting the CD93 pathway offers a promising strategy to improve cancer immunotherapy outcomes.
• Further research into CD93-mediated signaling could lead to more effective anti-cancer treatments.